Literature DB >> 9536446

Effects of mu opioid agonists alone and in combination with cocaine and D-amphetamine in rhesus monkeys trained to discriminate cocaine.

S S Negus1, M B Gatch, N K Mello.   

Abstract

Psychomotor stimulants and mu opioid agonists are often used together by polydrug abusers, and it has been suggested that this form of polydrug abuse may result from the ability of stimulants and mu agonists to enhance each other's abuse-related effects. To investigate this possibility, the present study examined stimulant-opioid interactions in rhesus monkeys trained to discriminate cocaine. Specifically, the effects of the mu opioid agonists heroin, alfentanil, fentanyl, and morphine administered alone or in combination with cocaine or d-amphetamine were examined in five monkeys trained to discriminate 0.4 mg/kg cocaine (IM) from saline in a two-lever, food-reinforced drug discrimination procedure. When administered alone, the rapid onset mu agonists heroin (0.032-0.32 mg/kg) and alfentanil (0.01-0.1 mg/kg) substituted completely for cocaine in three of five monkeys but produced primarily saline-appropriate responding in the other two monkeys. The slower onset mu agonists fentanyl (0.0056-0.056 mg/kg) and morphine (0.56-10 mg/kg) substituted for cocaine in only one of five monkeys. When administered as pretreatments to cocaine, morphine and fentanyl increased levels of cocaine-appropriate responding produced by low doses of cocaine in some monkeys. Morphine pretreatment also increased levels of cocaine-appropriate responding produced by low doses of amphetamine in some monkeys. However, in other monkeys, morphine and fentanyl pretreatment did not alter the discriminative stimulus effects of cocaine or amphetamine. These results indicate that there are substantial individual difference in the effects of mu agonists in cocaine-discriminating rhesus monkeys. In some monkeys, mu agonists mimic or enhance the discriminative stimulus of cocaine, whereas in other monkeys, mu agonists neither mimic nor enhance the effects of stimulants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9536446     DOI: 10.1016/S0893-133X(97)00163-2

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  6 in total

1.  Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents.

Authors:  Neil E Paterson; Allison Fedolak; Berend Olivier; Taleen Hanania; Afshin Ghavami; Barbara Caldarone
Journal:  Pharmacol Biochem Behav       Date:  2010-03-25       Impact factor: 3.533

2.  Asymmetric generalization and interaction profiles in rhesus monkeys discriminating intravenous cocaine or intravenous heroin from vehicle.

Authors:  Donna M Platt; James K Rowlett; Roger D Spealman
Journal:  J Pharmacol Exp Ther       Date:  2009-12-04       Impact factor: 4.030

3.  Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.

Authors:  Jun-Xu Li; Lance R McMahon; Lisa R Gerak; Ginger L Becker; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2008-05-10       Impact factor: 4.530

4.  Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys.

Authors:  S Stevens Negus; Ashley E Bear; John E Folk; Kenner C Rice
Journal:  Eur J Pharmacol       Date:  2008-11-11       Impact factor: 4.432

5.  Effects of chronic fentanyl administration on behavioral characteristics of mice.

Authors:  Kazuki Fujii; Yumie Koshidaka; Mayumi Adachi; Keizo Takao
Journal:  Neuropsychopharmacol Rep       Date:  2018-12-01

Review 6.  Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail.

Authors:  Hanis Mohammad Hazani; Isa Naina Mohamed; Mustapha Muzaimi; Wael Mohamed; Mohamad Fairuz Yahaya; Seong Lin Teoh; Rashidi Mohamed Pakri Mohamed; Mohd Fadzli Mohamad Isa; Sundus Mansoor Abdulrahman; Ravi Ramadah; Mohammad Rahim Kamaluddin; Jaya Kumar
Journal:  Front Pharmacol       Date:  2022-04-07       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.